2026-06-14T03:43:14Zhttps://repisalud.isciii.es/rest/oai/request

oai:repisalud.isciii.es:20.500.12105/132052024-09-27T09:35:26Zcom_20.500.12105_19604com_20.500.12105_2051col_20.500.12105_19605

00925njm 22002777a 4500 dc Garcia-Lunar, Ines author Pereda, Daniel author Ibáñez, Borja author Garcia-Alvarez, Ana author 2020-11 The autonomic nervous system (ANS) and renin-angiotensin-aldosterone system (RAAS) are involved in many cardiovascular disorders, including pulmonary hypertension (PH). The current review focuses on the role of the ANS and RAAS activation in PH and updated evidence of potential therapies targeting both systems in this condition, particularly in Groups 1 and 2. State of the art knowledge in preclinical and clinical use of pharmacologic drugs (beta-blockers, beta-three adrenoceptor agonists, or renin-angiotensin-aldosterone signaling drugs) and invasive procedures, such as pulmonary artery denervation, is provided. Cells. 2020; 9(11):2521 10.3390/cells9112521 2073-4409 Cells 33266371 http://hdl.handle.net/20.500.12105/13205 Neurohormonal Modulation as a Therapeutic Target in Pulmonary Hypertension.